Anavex Life Sciences Corp (AVXL)

[Joseph_K]

But I didn't ask you about the Odds Ratio. You wrote about

the unusual application of Odds Ratios and lack of primary endpoint time/response charts.

I asked,

As for the "lack of primary endpoint time/response charts," why do you feel Anavex's claims stated in this earlier post of mine fail to fill that void?

with an embedded link to that earlier post. I'll spell out what was in my "earlier post," which you seemed to have ignored:

•ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks
•Mean difference in ADAS-Cog score change of -1.85 points

and

•[with respect to CDR-SB scores] ANAVEX 2-73 treatment slowed clinical decline in cognition and function assessed by 27%
compared to placebo
•ANAVEX®2-73 treatment difference in mean score change of -0.42 points

You aren't saying those two claims (about the 45% and 27%) are invalidated by how Anavex handled the totally independent claim about Odds Ratio, are you?

Look at the 12-5-2022 conference call, at about the 22-minute mark, and you'll see, for ADAS-Cog, that Anavex has laid out the Baseline and Week-48 scores, for the Placebo group and for the Anavex 2-73 group; it includes the mean change for each, the relative reduction in decline between the mean changes for the two groups, figures for 95% Cl (which I believe is Confidence Level, yes?), and the P-value (0.033). For CDR-SB, look at that same conference call at about the 19-minute mark.

I'm asking you, in our newly-born "Due Diligence forum," why doesn't this data satisfy your desire for "primary endpoint time/response charts"?